Verrica Pharmaceuticals Inc. (VRCA) Misses Q1 EPS by 41c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts VRCA Hot Sheet
Join SI Premium – FREE
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q1 EPS of ($0.41). Revenue for the quarter came in at $5 million.
For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- Encore Capital Inc. (ECPG) PT Raised to $140 at Citizens on Material Upside to EPS, KPI Estimates
- TD Cowen Downgrades Linamar Corp (LNR:CN) (LIMAF) to Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
